The Readout Loud

336 Episodes

1. Episode 35: Biotech's October slump, the precise cost of precision, and breaking postpartum silence

   Published: 11/1/2018
2. Episode 34: Pharma at the ballot box, the latest Alzheimer's argument, and a rare disease dilemma

   Published: 10/25/2018
3. Episode 33: Drug prices on TV, immortal blockbusters, and genetic privacy

   Published: 10/18/2018
4. Episode 32: Fake friends at the FDA, cancer counter-narratives, and biotech's bear turn

   Published: 10/11/2018
5. Episode 31: Nobel snubs, millenial founders, and a new kind of lightning round

   Published: 10/4/2018
6. Episode 30: A fish oil epiphany, VC monopolies and ketamine clinics

   Published: 9/27/2018
7. Episode 29: A Hong Kong heat-check, a $20 million wrist slap, and pharma's (other) diversity problem

   Published: 9/20/2018
8. Episode 28: Founders' funds, doctors' disclosures, and the subtle art of beeping

   Published: 9/13/2018
9. Episode 27: Live from Boston!

   Published: 9/6/2018
10. Episode 26: FDA shows its teeth, biotech fish oil might be pointless, & treating McCain's cancer

    Published: 8/30/2018
11. Episode 25: A genome-editing first, Trump on Wall Street, and biotech red flags

    Published: 8/23/2018
12. Episode 24: A lesson in startup jargon, pharma's bare Alzheimer's cupboard, and the cost of CAR-T

    Published: 8/16/2018
13. Episode 23: Congressional insider trading, PETA and fake meat, & doctors vs. fund managers

    Published: 8/9/2018
14. Episode 22: Biotech's battle for talent, Sanofi's second act, and climbing Mt. Everest

    Published: 8/2/2018
15. Episode 21 - A debatable Alzheimer's breakthrough, Gilead's golden age, and "robust" data

    Published: 7/26/2018
16. Episode 20 - CRISPR freakouts, drug prices meet elections, and a busy earnings season

    Published: 7/19/2018
17. Episode 19: Trump's telephonic prowess, Biogen's mysterious future, & the rise of 'hypelines'

    Published: 7/12/2018
18. Episode 18: Biotech's six-month review, how to become a day trader and soul-searching analysts

    Published: 7/5/2018
19. Episode 17: A friendly FDA, biosimilar awkwardness and how to sell drugs in China

    Published: 6/28/2018
20. Episode 16: Sarepta's big week, Theranos' legal woes and parsing AI hype

    Published: 6/21/2018